TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05302921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation Therapy
Description: Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease.
Study: NCT06639724

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
Description: Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
Study: NCT06156163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation training
Description: The exercise program will be applied 2 days/week for 8 weeks, with the addition of progressive perturbation conditions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise program will be applied 2 days/week for 8 weeks.
Study: NCT04795466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Biological sub-cutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo subcutaneous injection
Study: NCT05321043

Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin B2 labeling
Description: Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.
Study: NCT06266806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Consultancy Program to Develop Breastfeeding Self-Efficacy Resources
Description: Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP) was developed based on Denis's Breastfeeding Self-Efficacy theory along with the hypnobreastfeeding philosophy. In the individual counseling program focusing on the philosophy of hypnobreastfeeding, it will be emphasized that breastfeeding is an intuitive, natural, and unique process. Techniques such as affirmations, breathing exercises, relaxation, endorphin, serotonin, and oxytocin-enhancing practices will be used. Concepts from Dennis' breastfeeding self-efficacy theory will be integrated into the training program. The individual counseling program will be carried out by adult education criteria, methods such as slide presentation, three-dimensional models, video, role-play, peer opinions with positive breastfeeding experiences, case discussion, and question and answer will be used.
Study: NCT06254313

Intervention type: OTHER
Intervention: Additional tubes and LBA
Description: 4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)

Intervention type: OTHER
Intervention: Additional tubes and LBA
Description: 4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)

Intervention type: OTHER
Intervention: Additional tubes and LBA
Description: 4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)
Study: NCT05398029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-101
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-101
Description: Intravenous (IV) infusion.
Study: NCT05871905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591
Description: C14 TY-9591
Study: NCT06468280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local treatment (Surgical)
Description: Radical gastrectomy with standard D2 lymphadenectomy will be performed, along with radical surgery for resectable metastatic lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 Monoclonal Antibody
Description: PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX Chemotherapy Regimen
Description: Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX Chemotherapy Regimen
Description: Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Treatment (Non-surgical)
Description: Additional local treatment for unresected metastatic lesions during phase 2 systemic therapy is permitted, including:~* Bone metastasis, distant lymph nodes, adrenal metastasis: Radiation therapy.~* Lung and liver metastasis: Radiofrequency ablation, interventional embolization, or radiation therapy.~* Peritoneal metastasis: Hyperthermic intraperitoneal chemotherapy (HIPEC).~* Other metastatic lesions: Non-surgical treatment options discussed by the multidisciplinary team.
Study: NCT06087536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMN6
Description: Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
Study: NCT06137963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transform10 Diabetes Prevention Program
Description: The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~* Strategies to overcome emotional eating using cognitive behavioral therapy principles.~* Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~* An introductory-level course for increasing muscle and bone density foundation via strength training.~* Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation.

Intervention type: OTHER
Group type: OTHER
Intervention: Transform10 Diabetes Prevention Program
Description: The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~* Strategies to overcome emotional eating using cognitive behavioral therapy principles.~* Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~* An introductory-level course for increasing muscle and bone density foundation via strength training.~* Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation.
Study: NCT04939272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 for each cycle.~Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Patients receive venetoclax PO QD on days 1-28 for each cycle. Venetoclax will have a weekly dose ramp up in cycle one from 20mg, 50mg, 100mg, 200mg, and then 400mg daily thereafter starting from cycle 2.
Study: NCT06212414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Programme
Description: Intervention based on Acceptance and Commitment Therapy, mindfulness, and compassion approaches

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: This intervention promotes the sharing of cancer-related experiences, active listening, and a sense of community between participants
Study: NCT04769076

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel（Albumin-bound）
Description: Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
Study: NCT05151926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full weight-bearing
Description: Instruction for full and immediate weight-bearing postoperatively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial weight-bearing
Description: Instruction for partial weight-bearing for 6 weeks postoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Description: Intramedullary nailing of the fractured tibial shaft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nailing
Description: Intramedullary nailing of the fractured tibial shaft.
Study: NCT05936424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise Leg
Description: One will perform unilateral resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise Leg
Description: One will perform unilateral resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise Leg
Description: One will perform unilateral resistance exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Exercise Control Leg
Description: One leg will serve as a non-exercise control
Study: NCT04933552

Intervention type: OTHER
Intervention: Siponimod
Description: Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod, that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05275725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
Study: NCT05898711

Intervention type: DEVICE
Intervention: Fish skin graft
Description: Kerecis Fish Skin Graft - SurgiBind
Study: NCT06129747

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Weeks 1, 2 and 3~* Weeks 1, 2 and 3 will include 5 days of treatment.~* One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes.
Study: NCT04876248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT06073626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational agent (RA) / Chatbot
Description: Consists of clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among Black cancer survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Consists of clinical letter and recommendation for genetic testing for hereditary cancer risk among Black cancer survivors.
Study: NCT05281380

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: GIKAVI
Description: Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
Study: NCT05134948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986213
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986213
Description: Specified dose on specified days
Study: NCT05584761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unrelated umbilical cord blood
Description: A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection.
Study: NCT05729347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality headset with calming scenery
Description: Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
Study: NCT06534853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times.
Study: NCT05150002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
Study: NCT06534853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition
Description: The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: A comprehensive therapeutic regimen that includes a 10-minute session of hot pack therapy specifically targeted at the low back region. In addition to this, participants will receive trigger point release therapy to alleviate muscle tension.The treatment plan also incorporates a tailored exercise protocol designed to enhance back health and strength. This protocol includes:~1. Back isometric exercises~2. Bridging exercises~3. Cat and camel stretches~4. Prone press-ups~5. Abductor strengthening exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: A comprehensive therapeutic regimen that includes a 10-minute session of hot pack therapy specifically targeted at the low back region. In addition to this, participants will receive trigger point release therapy to alleviate muscle tension.The treatment plan also incorporates a tailored exercise protocol designed to enhance back health and strength. This protocol includes:~1. Back isometric exercises~2. Bridging exercises~3. Cat and camel stretches~4. Prone press-ups~5. Abductor strengthening exercises
Study: NCT04679766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ice cream cone technique with immediate implant as a flapless bone regenerative method in management of patients with labial plte dehiscence
Description: Atraumatic extraction will be done The extraction socket will be debrided to remove any residual debris using surgical curettes Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence. Implant placement will be done. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using non-resorbable sutures
Study: NCT06355895

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized high-carbohydrate meal
Description: 8 ounces of Ensure® nutritional protein shake or a similar meal
Study: NCT05753020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CKM Jumpstart Tool
Description: The CKM JumpStart Tool is a 1-page handout that describes the values of a patient and words that a providers can try with the patient to explore the patient' values more and to provide a values-based introduction to CKM. The values described in the CKM JumpStart Tool is based on a patient's response to a single validated question that we will ask the patient at T1, if they had to choose, do they value care directed at longevity or comfort. Using the patient's answer to the values question, study staff will generate a CKM JumpStart Tool prior to their upcoming clinic visit with their nephrologist. Study staff will inform the patient that their response to the values question will be shared with their provider prior to their next clinic visit and that their providers might bring up their values and treatment options for kidney disease, if the situation permits. We will share the CKM Jumpstart Tool with their provider and provide instruction on how to use the Tool.
Study: NCT05187624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7428731
Description: Participants will receive RO7428731 as described.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7428731
Description: Participants will receive RO7428731 as described.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7428731
Description: Participants will receive RO7428731 as described.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7428731
Description: Participants will receive RO7428731 as described.
Study: NCT06528041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water